Sheila Gujrathi, MD
Sheila Gujrathi, MD is a biotech entrepreneur, healthcare investor, and drug developer with over 25 years of experience. She serves as chair of ADARx, Ventyx, and Lila Bio, and director of Janux. She previously served as chair of Turning Point (acquired by BMS for $4.1B) and ImmPACT Bio (acquired by Lyell). Dr. Gujrathi is the co-founder and former CEO of Gossamer Bio. Prior to Gossamer Bio, she served as chief medical officer of Receptos (acquired by Celgene for $7.2B). At Receptos, she led the development of Zeposia®, which is approved for multiple sclerosis and for ulcerative colitis. Previously, she was the immunology therapeutic area head at BMS and held multiple roles in immunology and oncology at Genentech. Earlier in her career, she was a management consultant at McKinsey and completed her medical training at Harvard, UCSF and Stanford.
Dr. Gujrathi has earned multiple awards, including Corporate Directors Forum Director of the Year; Healthcare Technology Report Top 25 Women Leaders; Athena Pinnacle Award, and was named among the Fiercest Women in Life Sciences. Dr. Gujrathi is passionate about making the working world safe and inclusive for women and other minority groups. She is co-founder of the Biotech CEO Sisterhood and the South Asian Biopharma Alliance. She received both her M.D. and B.S. in biomedical engineering in the accelerated Honors Program in Medical Education at Northwestern University where she was the 2024 commencement speaker.
About the Sisterhood
The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry. Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry. As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness. Since its inception in 2022, the Biotech CEO Sisterhood has grown to 300+ members. To follow our progress and learn more, please follow us on LinkedIn.
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.